Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: JOHN W. who wrote (3676)	1/26/1998 9:19:00 PM
From: David S.	Respond to of 6136

you used the phrase "worse than anybody thought". 1)cleary an innacurate + emotional statement 2) doubt if the product is effective at viral supression, rash as a potential side effect will deter physicians from prescribing it, as...3) PI's as a class of drugs each have their own side effects. yawn. PS - I am pleased that Viracept is on the market and hope for continued progress against this disease.

To: JOHN W. who wrote (3676)	1/26/1998 10:24:00 PM
From: David S.	Read Replies (2) \| Respond to of 6136

Since John W. says that Agouron has the cure for the common cold, I thought you all would want to know that these firms are all biotech firms that should therefore be shorted since their work in developing biotech solutions for the common cold will obviously, be worthless since everything AGPH does turns to gold, uh...what happened to AGPH's psoriasis product, oh well - who cares about the small stuff anyway? Bayer BAYZ9700 Phase 1 Boehringer Soluble ICAM-1 Phase II Lilly LY354400 preclinical ViroPharma Pleconaril Phase II, colds in asthmatics By the way, what phase is AGPH's rhinovirus 3c protease inhibitor in, John? OK group, can you say "picornavirus"?